Maltodextrin based proniosomes of nateglinide: Bioavailability assessment

The present study delineates the fabrication of maltodextrin based proniosomes of nateglinide and their potential as controlled delivery system for diabetic therapy. New Zealand albino male rabbits have been used as animal model for in vivo study. To evaluate the bioavailability of nateglinide proniosome, a rapid, simple and sensitive HPLC method with photodiode array detection was developed and validated to determine nateglinide in rabbit plasma. Chromatographic separation was achieved by a reverse phase C18 column using a mixture of acetonitrile:methanol:10 mM phosphate buffer (pH 3.5) in the ratio of 56:14:30 (%v/v) as the mobile phase at a flow rate of 1.0 ml/min and quantified based on drug/IS peak area ratios. Gliclazide was used as the internal standard. The intra- and inter-day relative standard deviations of four tested concentrations were below 2%. The nateglinide proniosome formulation exhibited significantly higher plasma concentration than those of pure drug. The study revealed that the rate and extent of absorption of nateglinide from the proniosomal formulation was comparatively enhanced that of pure drug. Maltodextrin based proniosomes of nateglinide is not only simple and cost efficient delivery but also offers a useful and promising carrier for diabetic therapy through oral administration.